Close

XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. NVDA
10. MINN


Go back to XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD
(NASDAQ: XBIT) Delayed: 8.18 +0.23 (2.89%)
Previous Close $7.95    52 Week High $25.00 
Open $7.75    52 Week Low $6.36 
Day High $8.55    P/E N/A 
Day Low $7.75    EPS $0.00 
Volume 154,408